Stock Analysis of AbbVie Inc (ABBV) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Close 144.15
Change 0.740 / 0.516 %
Volume 3445.93 K
Vol Change -220439.00 / 6.01 %
IndustryDrug Manufacturers-General
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Very Low Growth Stock
Value Index Very Low Value Stock
Profitability Index Low Profitability Stock
Stability Index Very Low Stability Stock

Fundamental View of AbbVie Inc

Highs/Lows of AbbVie Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week139.09 3.64 % 0.425 % 145.49137.6504-Dec-2329-Nov-23
Two Week138.31 4.22 % 0.493 % 145.49137.6504-Dec-2329-Nov-23
One Month141.42 1.93 % 4.85 % 145.49135.8504-Dec-2309-Nov-23
Three Month148.2 2.73 % 1.20 % 154.88135.8520-Sep-2309-Nov-23
Six Months136.87 5.32 % 6.71 % 154.88130.9620-Sep-2328-Jun-23
One year163.66 11.92 % 12.23 % 168.11130.9606-Jan-2328-Jun-23
Two year118.85 21.29 % 0.691 % 166.2130.9625-Apr-2328-Jun-23
Five year90.55 59.19 % 69.25 % 168.1162.5506-Jan-2323-Mar-20
Ten year49.67 190.22 % 154.89 % 175.9145.4508-Apr-2222-Oct-15

Technical View of AbbVie Inc

Charts of AbbVie Inc

Returns of AbbVie Inc with Peers
1 Week3.64%5.02%3.58%1.28%
1 Mth1.93%4.98%1.63%6.72%
3 Mth-2.73%-0.997%-4.35%-1.72%
1 Year-11.92%-11.18%-4.53%10.00%
2 Year21.29%-0.314%43.25%23.74%
5 Years59.19%8.80%40.78%23.34%

Compare Fundamentals of AbbVie Inc with Peers
Debt To Equity3.670.5160.6670.444
Revenue58054.00 M
3.30 %
94943.00 M
1.25 %
59283.00 M
21.72 %
51828.00 M
1.98 %
Net Income11836.00 M
2.55 %
17941.00 M
14.07 %
14519.00 M
11.27 %
6955.00 M
71.05 %

Technicals of AbbVie Inc with Peers
Technical / StockABBVJNJMRKNVS
MACD Abv SignalTrueTrueTrueTrue
Price Above 50 MATrueTrueTrueTrue
Price Above 200 MAFalseFalseFalseTrue

About : AbbVie Inc

Address : 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
Tel : 847 932 7900
Code : ABBV, ISIN : US00287Y1091, Exchange : NYSE, Country : USA
Fiscal Year End : December
IPO date : 02_Jan_2013
Employee Count : 50000

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Note : All Data Generated at the End of Trading Hours (EOD Data)